 The null hypothesis of this study states that safety outcomes stent thrombosis, non-fatal MI, death with Xience V will be equivalent to historical and contemporaneous controls; effectiveness outcomes target lesion and target vessel revascularization with Xience V will be superior to historical and contemporaneous BMS controls, and equivalent to historical and contemporaneous DES controls; and the need for crossover to another stent type will be equal to that observed with historical DES controls. Outcomes will be reported using contemporary measures of clinical outcomes and analyzed using Cox proportional hazards survival analysis methodology. These data should provide important information on the clinical effectiveness and safety of Xience V in routine practice. 